Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma

10.08.2022 - WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, ...

Related Keywords

Poland ,Polish ,Tom Shepherd ,Bartosz Sawulski ,Guillaume Van Renterghem ,International Investor Relations ,Contract Development ,Linkedin ,Twitter ,Manufacturing Organization ,Chief Scientific Officer ,Chief Executive Officer ,Targeted Protein Degradation ,Captor Therapeutics ,Investor Relations ,